Surgery may replace chemo for some testicular cancer patients

NCT ID NCT02537548

Ongoing Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a surgery called retroperitoneal lymph node dissection (RPLND) can be used as the first treatment for men with early-stage testicular seminoma that has spread to lymph nodes in the abdomen. The goal is to see if this surgery can control the cancer while causing fewer long-term side effects than standard treatments like chemotherapy or radiation. About 55 men with small lymph nodes (1-3 cm) are being enrolled to track how many stay cancer-free after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Retroperitoneal lymph node dissection (RPLND) surgery
What this could lead to: If successful, this surgery could become a first-line treatment option for early-stage testicular seminoma, reducing the risk of long-term side effects like second cancers and heart disease.
What could go wrong: This is a small, early-phase trial with only 55 participants, so results may not apply to everyone. The surgery itself carries risks like bleeding, infection, and nerve damage, and some patients may still experience cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHADENOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphadenopathy lymphatic system disorder seminoma testicular seminoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHADENOPATHY STAGE I TESTICULAR SEMINOMA STAGE II TESTICULAR SEMINOMA

Contacts and locations

Locations

Emory University

Atlanta, Georgia, 30322, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Loma Linda University Medical Center

Loma Linda, California, 92350, United States
Madigan Army Medical Center

Tacoma, Washington, 98431, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903-2681, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21205, United States
Stanford University Hospitals & Clinics

Stanford, California, 94305, United States
Stephenson Cancer Center, University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
UTSouthwestern Medical Center

Dallas, Texas, 75390-9110, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Colorado Hospital - Aurora

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.